Show Notes
The UK has long been a world leader for clinical trials and life sciences research. But after losing ground post-COVID and post-Brexit, the country has begun to rethink the landscape for clinical trials. In this free New Scientist podcast, we meet the chair of the UK review into commercial clinical trials, James O'Shaughnessy, and ask how the independent review has influenced the reinvention of the clinical trials infrastructure for a new age of medicine.
Sponsored by the UK Department for Business and Trade and the Medicines and Healthcare products Regulatory Agency
Hosted on Acast. See acast.com/privacy for more information. Learn more about your ad choices. Visit megaphone.fm/adchoices
More from New Scientist Colab Podcasts
💬 The longevity space isn’t just for humans. Science is uncovering new ways to keep our pets healthier for longer too. New research is finally uncovering why our dogs and cats slow down with age - and how we can slow that process.
💬 Over the last decade, advances in subsurface imaging have meant we’re able to see deep within our planet with unfathomable detail - pinpointing vast geological structures beneath our oceans with unprecedented accuracy.
The production of medicines is a high-stakes industry where efficiency and environmental impact often collide. Given that the pharmaceutical industry is one of society’s biggest polluters, solving this challenge requires massive, cross-continent collaboration to spark real change.